{
    "clinical_study": {
        "@rank": "139385", 
        "arm_group": {
            "arm_group_label": "GLP-1 analog", 
            "arm_group_type": "Experimental", 
            "description": "Liraglutide, 0.6 to 1.8 mg per day or Exenatide, 5 to 10 \u00b5g twice a day."
        }, 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate after 4 to 6 months the effects of a GLP-1 analog\n      treatment on psoriatic skin lesions in patients with type 2 diabetes."
        }, 
        "brief_title": "Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 2 Diabetes", 
            "Psoriasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Psoriasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The objective of this study is to analyse short and medium-term efficacy on clinical,\n      immunological and histopathological parameters of a GLP-1 receptor agonist on moderate to\n      severe psoriasis plaques in a group of patients with type 2 diabetes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetic patients treated with oral anti-hyperglycaemic agents and/or insulin\n             and presenting stable psoriasis plaques for at least one year, which failed to\n             respond to previous systemic and/or topical treatments.\n\n        Exclusion Criteria:\n\n          -  Type 1 diabetes\n\n          -  Secondary diabetes\n\n          -  Liver, renal or pancreatic disease\n\n          -  Previous treatment with GLP-1 agonist or DPP-4 inhibitors agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01687582", 
            "org_study_id": "UCL-DIAB-02"
        }, 
        "intervention": {
            "arm_group_label": "GLP-1 analog", 
            "description": "GLP-1 analog treatment", 
            "intervention_name": "GLP-1 analog", 
            "intervention_type": "Drug", 
            "other_name": "Liraglutide, Victoza or Exenatide, Byetta."
        }, 
        "intervention_browse": {
            "mesh_term": "Exenatide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "type 2 diabetes", 
            "psoriasis", 
            "exenatide", 
            "liraglutide"
        ], 
        "lastchanged_date": "September 13, 2012", 
        "location": {
            "contact": {
                "email": "martin.buysschaert@uclouvain.be", 
                "last_name": "Martin Buysschaert, PhD", 
                "phone": "+3227645475"
            }, 
            "contact_backup": {
                "email": "vanessa.preumont@uclouvain.be", 
                "last_name": "Vanessa Preumont, MD", 
                "phone": "+3227645475"
            }, 
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "1200"
                }, 
                "name": "Cliniques universitaires Saint-Luc"
            }, 
            "investigator": {
                "last_name": "Martin Buysschaert, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical and Histopathological Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients", 
        "overall_contact": {
            "email": "martin.buysschaert@uclouvain.be", 
            "last_name": "Martin Buysschaert, PhD", 
            "phone": "+3227645475"
        }, 
        "overall_official": {
            "affiliation": "Cliniques universitaires Saint-Luc", 
            "last_name": "Martin Buysschaert, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Improvement of PASI score", 
            "safety_issue": "No", 
            "time_frame": "4 to 6 months"
        }, 
        "reference": [
            {
                "PMID": "22227407", 
                "citation": "Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012 Feb;38(1):86-8. doi: 10.1016/j.diabet.2011.11.004. Epub 2012 Jan 9."
            }, 
            {
                "PMID": "21744074", 
                "citation": "Hogan AE, Tobin AM, Ahern T, Corrigan MA, Gaoatswe G, Jackson R, O'Reilly V, Lynch L, Doherty DG, Moynagh PN, Kirby B, O'Connell J, O'Shea D. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011 Nov;54(11):2745-54. Epub 2011 Jul 9."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01687582"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cliniques universitaires Saint-Luc- Universit\u00e9 Catholique de Louvain", 
            "investigator_full_name": "Buysschaert", 
            "investigator_title": "Head of Department of Endocrinology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "number of patients with weight loss", 
                "measure": "Evolution of BMI (body mass index)", 
                "safety_issue": "No", 
                "time_frame": "4 to 6 months"
            }, 
            {
                "description": "cytokines and T cells", 
                "measure": "Evolution of immunological data", 
                "safety_issue": "No", 
                "time_frame": "4 to 6 months"
            }, 
            {
                "description": "thickness, dermis infiltrate in skin plaques and in control areas", 
                "measure": "Evolution of histopathological data", 
                "safety_issue": "No", 
                "time_frame": "4 to 6 months"
            }, 
            {
                "description": "HbA1c", 
                "measure": "Evolution of glycaemic control", 
                "safety_issue": "No", 
                "time_frame": "4 to 6 months"
            }, 
            {
                "description": "number of participants with biological adverse effects (pancreatitis enzymes)", 
                "measure": "Evolution of routine laboratory measures", 
                "safety_issue": "Yes", 
                "time_frame": "4 to 6 months"
            }, 
            {
                "description": "weight", 
                "measure": "Evolution of BMI", 
                "safety_issue": "No", 
                "time_frame": "4 to 6 months"
            }
        ], 
        "source": "Cliniques universitaires Saint-Luc- Universit\u00e9 Catholique de Louvain", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cliniques universitaires Saint-Luc- Universit\u00e9 Catholique de Louvain", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}